uniQure NV (QURE) Actualités

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene...

Form 8-K - Current report

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading...

Form 8-K - Current report

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data...